Multiple sclerosis trials in France

In France 70 Also abroad 503

70 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Where
Besancon Cedex, Brest, Libourne Cedex, Nancy, Nantes Cedex, Nice, Nimes Cedex 9, Paris, Poissy, Reims Cedex, Rennes, Rouen, Toulouse
Age
18 years to 60 years
People
990 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00
No phaseNot yet taking people in France
Neurogenetics and Multi-omics of Neuroinflammatory Diseases in Multiplex Families to Improve Patients Health
Where
Bron, Nantes, Nice, Paris, Rennes
Age
15 years and over
People
500
Run by
Institut National de la Santé Et de la Recherche Médicale, France
See details and how to joinNCT07902479
Phase 3Taking people
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Where
Amiens Cedex 1, Bordeaux, Bron, Gonesse, Grenoble Cedex 9, Montpellier Cedex 5, Nancy, Nice, Orsay, Paris, Rennes, Rouen, Strasbourg Cedex 2, Toulouse
Age
18 years to 60 years
People
705 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00
No phaseTaking people
Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity
Where
Montpellier, Nantes, Nice, Nîmes, Paris, Rennes
Age
18 years to 55 years
People
84
Run by
Centre Hospitalier Universitaire de Nīmes
See details and how to joinNCT07292480
No phaseTaking people
Switch to Ofatumumab and Level of Immunoglobulins
Where
Lille
Age
18 years to 65 years
People
115
Run by
University Hospital, Lille
See details and how to joinNCT07625800
Phase 3Taking people
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
Where
Grenoble Cedex 9, Lille Cedex, Nice, Saint-Herblain
Age
18 years to 64 years
People
386 worldwide
Run by
Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00
Phase 3Taking people
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
Where
Amiens, Bayonne, Besancon Cedex, Bordeaux, Brest, Bron, Caen Cedex 9, Clermont Ferrand Cedex 1, Lille Cedex, Montpellier Cedex 5, Nice, Nimes Cedex 9, Poissy, Saint-Herblain, Strasbourg Cedex 2
Age
18 years and over
People
500 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06675955 · EU 2023-507633-21-01
No phaseTaking people
Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group
Where
Bordeaux
Age
25 years to 35 years
People
160
Run by
University Hospital, Bordeaux
See details and how to joinNCT05754593
No phaseTaking people
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
Where
Bordeaux
Age
18 years and over
People
150
Run by
University Hospital, Bordeaux
See details and how to joinNCT04798651
Phase 3Taking people
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Where
Besançon, Bordeaux, Clermont-Ferrand, Lille Cedex, Marseille, Nice, Nîmes, Paris, Poissy, Poitiers, Strasbourg Cedex 2, Toulouse, Tours
Age
40 years to 70 years
People
400 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06846281 · EU 2023-509275-17-00
Phase 3Taking people
Remyelination in Multiple Sclerosis: a PET-MR longitudinal study investigating individual profiles of myelin repair and the contribution of neuroinflammation (SMART in MS)
Where
Orsay, Paris
Age
18 years to 64 years
People
60
Run by
Assistance Publique Hopitaux De Paris
See details and how to joinNCT05147532 · EU 2024-512761-13-00
Phase 3Taking people
A Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
Where
Nimes Cedex 9, Reims Cedex
Age
18 years to 64 years
People
125 worldwide
Run by
Amgen Inc.
See details and how to join2024-512914-16-00 · EU 2024-512914-16-00
No phaseTaking people
Evaluation of the NEUROSWING Orthosis on Walking Speed in a Population With Dorsal and/or Plantar Flexor Deficits, With a View to a Reimbursement Application
Where
Hérouville-Saint-Clair, La Membrolle-sur-Choisille
Age
18 years and over
People
34
Run by
ÖSSUR France
See details and how to joinNCT07108088
Phase 2Not yet taking people in France
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
Where
Bron, Le Kremlin Bicetre Cedex
Age
10 years to 17 years
People
25 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07503340 · EU 2025-524164-37-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Where
Ajaccio, Amiens, Clermont-Ferrand, Grenoble, Lille, Limoges, Montpellier, Nancy, Nantes, Nice, Nîmes, Orsay, Paris, Poitiers, Rennes, Rouen, Strasbourg, Toulouse, Tours
Age
18 years to 65 years
People
1,275 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07225504
Phase 3Taking people
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Where
Calais, Colmar Cedex, Grenoble Cedex 9, Lille Cedex, Nice, Paris, Paris Cedex 19, Rennes Cedex 9, Saint-Herblain
Age
18 years to 60 years
People
160 worldwide
Run by
Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00
Phase 2Taking people
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Where
Bordeaux, Bron, Clermont-Ferrand, Montpellier Cedex 5, Nancy, Nimes Cedex 9, Paris, Rennes, Saint-Herblain, Strasbourg Cedex 2, Toulouse
Age
18 years to 60 years
People
360 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07282574 · EU 2025-521636-10-00
No phaseTaking people
Enhancing Self-Esteem in Patients With Multiple Sclerosis: A Randomised Controlled Trial of the Lexical Association Technique
Where
Grenoble
Age
18 years and over
People
160
Run by
University Hospital, Grenoble
See details and how to joinNCT07064291
Phase 3Taking people
LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS: CONSONANCE EXTENSION STUDY
Where
Amiens, Bayonne, Bordeaux, Bron, Caen Cedex 9, Clermont-Ferrand, Lille Cedex, Marseille, Montpellier Cedex 5, Nancy, Nantes Cedex 1, Nice, Nîmes, Rennes, Strasbourg Cedex 2
Age
18 years to 64 years
People
89
Run by
Centre Hospitalier Universitaire De Nice
See details and how to join2024-516433-13-00 · EU 2024-516433-13-00
Phase 3Taking people
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
Where
Le Kremlin-Bicetre, Montpellier Cedex 5, Strasbourg Cedex 2
Age
Up to 17 years
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-511686-11-00 · EU 2024-511686-11-00
No phaseTaking people
TWEAK, a New Biomarker for Predicting Inflammatory Relapses in Multiple Sclerosis
Where
Marseille
Age
18 years and over
People
50
Run by
Assistance Publique Hopitaux De Marseille
See details and how to joinNCT03974997
Phase 3Not yet taking people in France
ANTIBIOBONTA - Assessment of the interest of a peri-operative antibiotic strategy applied to patients with asymptomatic bacteriuria undergoing intra-vesical botulinum toxin A injections
Where
Bordeaux, Garches, Lille Cedex, Nantes, Paris, Paris Cedex 13, Pierre-Bénite, Rennes Cedex 9, Toulouse Cedex 9
Age
18 years and over
People
526
Run by
Centre Hospitalier Universitaire De Lille
See details and how to joinNCT05534399 · EU 2024-515107-19-00
Phase 4Not yet taking people in France
Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial
Where
Besancon Cedex, Bron, Caen Cedex 9, Clermont Ferrand Cedex 1, Créteil, Dijon, Grenoble Cedex 9, Libourne Cedex, Lille, Lille Cedex, Montpellier Cedex 5, Nantes Cedex 1, Nice, Nimes Cedex 9, Paris, Paris Cedex 13, Poitiers, Rennes, Rouen Cedex, St Germain En Laye Cedex, Talence, Toulouse, Tours
Age
18 years to 64 years
People
160
Run by
University Hospital, Toulouse
See details and how to joinNCT07818356 · EU 2025-525106-37-00
No phaseTaking people
Application of ihMT MRI in Multiple Sclerosis
Where
Marseille
Age
18 years to 45 years
People
85
Run by
Assistance Publique Hopitaux De Marseille
See details and how to joinNCT03600779
Phase 3Taking people
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
Where
Ajaccio, Amiens Cedex 1, Besançon, Bron, Clermont-Ferrand, Gonesse, Grenoble Cedex 09, Lille Cedex, Limoges Cedex 1, Montpellier Cedex 5, Nancy, Nice, Nîmes, Orsay, Paris, Poitiers, Rennes Cedex 9, Rouen Cedex, Saint-Herblain, Strasbourg Cedex 2, Toulouse, Tours
Age
18 years and over
People
677 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00